Headache and Migraine

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

The associate professor of neurology at Mayo Clinic College of Medicine discussed how migraine trials can evolve to better incorporate patient-centered outcomes that reflect daily function and quality of life. [WATCH TIME: 3 minutes]

A recently published position statement from the American Headache Society recommends annual screening for migraine in girls and women, highlighting the potential role of tools like the ID Migraine screener to improve identification.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Amaal Starling, MD, FAHS, FAAN. [LISTEN TIME: 16 minutes]

The associate professor of neurology at Mayo Clinic provided a breakdown of the real-world eptinezumab data from INFUSE and its implications for early, robust migraine intervention after CGRP failure.

Real-world INFUSE results show IV eptinezumab boosts good days and cuts monthly headache days for hard-to-treat migraine patients.

The associate professor of neurology at Mayo Clinic College of Medicine breaks down new real-world INFUSE findings and explains how clinicians should interpret the effectiveness of intravenous eptinezumab in patients with refractory, high-burden migraine. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In this Q&A, migraine expert Deena Kuruvilla, MD, FAAN, provided clinical context on the phase 4 COMPEL trial testing onabotulinumtoxinA as a preventive treatment of chronic migraine in diverse racial groups.

Off-label rimegepant was associated with patient-reported acute migraine improvement and no new safety signals in a small retrospective review of adolescent patients.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

New data suggest that prophylactic treatment with anti-calcitonin gene-related peptide monoclonal antibodies may be associated with improvements in sleep quality and daytime sleepiness among patients with migraine.

Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, demonstrated efficacy in children and adolescents with episodic migraine in full data release.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.